Therapeutic Advances in Musculoskeletal Disease最新文献

{"title":"MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions.","authors":"Namrata Singh, Jerry H Gurwitz, Sarah B Lieber","doi":"10.1177/1759720X261462685","DOIUrl":"10.1177/1759720X261462685","url":null,"abstract":"<p><p>Multiple chronic conditions (MCCs), also known as multimorbidity, are highly prevalent in adults with autoimmune and inflammatory rheumatic diseases (AIIRDs) and significantly complicate their management. This narrative review summarizes current literature on the epidemiology of MCCs in various AIIRDs, highlighting their association with adverse health outcomes and proposing future directions for care. MCCs are ubiquitous across AIIRDs, often exceeding rates seen in age-matched general populations, with prevalence as high as 86% in rheumatoid arthritis and 81.5% in systemic lupus erythematosus cohorts and notable patterns including cardiopulmonary and mental health disorders frequently observed. This substantial MCC burden is consistently linked to adverse outcomes, including increased all-cause mortality, reduced functional status, diminished health-related quality of life, accelerated disability, higher healthcare utilization, and increased costs, driven by chronic inflammation, lifestyle, and treatment effects. Therefore, rheumatology care must adopt a holistic, person-centered framework that actively recognizes and manages MCCs, leveraging multidisciplinary teams and integrating evidence-based interventions guided by frameworks such as the geriatric 5Ms and 5Ts to advance the science of MCCs in adults with AIIRDs and improve outcomes and optimize health-related quality of life in this complex patient population.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261462685"},"PeriodicalIF":3.3,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148593295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal osteoporosis therapy: treat-to-target and sequential strategies-a narrative review.","authors":"Irakli Tskhakaia, Maria I Danila","doi":"10.1177/1759720X261466911","DOIUrl":"10.1177/1759720X261466911","url":null,"abstract":"<p><p>Osteoporosis is a chronic skeletal disorder in which reduced bone strength confers sustained fracture risk, often necessitating long-term pharmacotherapy with a multi-phase approach rather than a single \"one and done\" drug choice. Contemporary guidelines increasingly advocate a treat-to-target (TTT), goal-directed approach: clinicians define an explicit target, most often a total hip <i>T</i>-score threshold that corresponds to a lower fracture risk than baseline; select initial therapy according to baseline risk; and reassess and adjust treatment intensity until that target is achieved and maintained. Within this framework, sequential strategies are central. Anabolic-first sequences (e.g., abaloparatide or teriparatide followed by alendronate, or romosozumab followed by alendronate or denosumab) consistently produce larger and more durable gains in bone mineral density and fracture risk reduction in very-high-risk patients than antiresorptive monotherapy. Transitions from long-term bisphosphonates to teriparatide are complicated by transient increased remodeling and modest hip BMD responses, whereas switching to romosozumab yields more robust bone mineral density (BMD) gains at the hip. Notably, denosumab discontinuation demands structured bisphosphonate \"exit\" therapy to avoid rebound bone loss and multiple vertebral fractures. Across all pathways, rare but serious adverse events (e.g., atypical femoral fractures, medication-related osteonecrosis of the jaw, cardiovascular events), patient adherence and persistence, and insurance coverage constraints strongly shape the feasibility and desirability of specific regimens. This narrative review synthesizes mechanistic and clinical evidence underlying TTT osteoporosis care, summarizes the evidence base for sequential osteoporosis pharmacotherapy, and proposes practical strategies to help clinicians choose, transition, and discontinue therapies while preserving skeletal gains and minimizing harm over decades of longitudinal osteoporosis care.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261466911"},"PeriodicalIF":3.3,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13392348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148580131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular safety of romosozumab versus denosumab for osteoporosis treatment: a multinational real-world data analysis.","authors":"Balqis Istiqomah Gusbela, Min Huei Hsu, Chun Feng Huang, Meng Huang Wu, Daniel C A Nugroho, Muhammad Solihuddin Muhtar, Christine Y Lu, Ming Hung Teng, Jason C Hsu","doi":"10.1177/1759720X261466904","DOIUrl":"10.1177/1759720X261466904","url":null,"abstract":"<p><strong>Background: </strong>Romosozumab and denosumab are two highly effective, widely used osteoporosis treatments. There has been no study directly comparing the effectiveness of romosozumab and denosumab in a clinical setting using large-scale, real-world data.</p><p><strong>Objectives: </strong>To evaluate the association between romosozumab and cardiovascular outcomes compared to denosumab in patients with osteoporosis.</p><p><strong>Design: </strong>Retrospective propensity score-matched cohort study.</p><p><strong>Methods: </strong>Using the TriNetX global health research network, we identified 59,058 patients aged 60 years or older with osteoporosis who initiated romosozumab (<i>n</i> = 5200) or denosumab (<i>n</i> = 53,858) between January 2019 and December 2024. After 1:1 propensity score matching, 2 balanced cohorts of 5192 patients each were obtained. Cardiovascular outcomes, including three-point major adverse cardiac events (3P-MACE ), 4P-MACE, 5P-MACE, individual MACE components, and other cardiovascular diseases (CVDs), were assessed across three follow-up periods: short-term (1 year), mid-term (3 years), and long-term (5 years). Primary analyses were conducted among patients without a prior cardiovascular history, and sensitivity analyses were performed among those with a prior cardiovascular history.</p><p><strong>Results: </strong>Among patients without a prior cardiovascular history, romosozumab was associated with significantly lower risks of 3P-MACE at 3-year (hazard ratio (HR) 0.645, 95% confidence interval (CI) 0.438-0.950, <i>p</i> = 0.023) and 5-year follow-up (HR 0.755, 95% CI 0.512-0.873, <i>p</i> = 0.028), and lower mortality at 3-year (HR 0.554, 95% CI 0.316-0.972, <i>p</i> = 0.038) and 5-year follow-up (HR 0.533, 95% CI 0.312-0.913, <i>p</i> = 0.028). No significant differences were observed at 1-year follow-up. In contrast, among patients with a prior cardiovascular history, romosozumab was associated with significantly higher risks of 4P-MACE, 5P-MACE, stroke, mortality, and chronic ischemic heart disease across all three follow-up time horizons.</p><p><strong>Conclusion: </strong>Romosozumab was associated with lower risks of 3P-MACE and mortality compared to denosumab among patients without a prior cardiovascular history at mid-term and long-term follow-up. In contrast, romosozumab was associated with consistently higher cardiovascular risks in patients with preexisting CVD. These findings highlight the importance of careful cardiovascular risk assessment prior to initiating romosozumab, particularly in patients with preexisting CVD. The 3P-MACE finding in patients without prior cardiovascular history is the primary confirmatory result; all other outcomes should be considered exploratory and hypothesis-generating.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261466904"},"PeriodicalIF":3.3,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148562974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic disease and risk of total knee arthroplasty among patients with knee osteoarthritis receiving intra-articular hyaluronic acid: a real-world cohort study.","authors":"Ya-Chi Chuang, Cheng-Chi Wang, I-Chieh Chen, Jun-Fu Lin, Ching-Heng Lin, Chien-Chih Wang","doi":"10.1177/1759720X261467265","DOIUrl":"10.1177/1759720X261467265","url":null,"abstract":"<p><strong>Background: </strong>Intra-articular hyaluronic acid (HA) is widely used in the management of knee osteoarthritis (OA); however, treatment responses vary substantially among patients. Cardiometabolic disease (CMD) has been increasingly recognized as a potential modifier of disease progression and treatment outcomes. This study aimed to evaluate the impact of cardiometabolic burden on clinically relevant outcomes in patients with knee OA receiving intra-articular therapy.</p><p><strong>Objectives: </strong>To evaluate the impact of cardiometabolic burden on clinically relevant outcomes in patients with knee OA receiving intra-articular therapy.</p><p><strong>Design: </strong>Real-world retrospective cohort study.</p><p><strong>Methods: </strong>We used the TriNetX Global Network to identify patients with knee OA who received intra-articular HA injections. CMD was defined as the presence of at least one cardiometabolic condition, including type 2 diabetes mellitus (T2DM), hypertension, or hyperlipidemia. Propensity score matching (1:1) was performed to balance baseline characteristics. The primary outcome was incident primary total knee arthroplasty (TKA) within 36 months. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models, and Kaplan-Meier analyses were performed to estimate cumulative incidence.</p><p><strong>Results: </strong>Among 50,833 eligible patients, 35,509 were classified into the CMD group and 15,324 into the control group. After propensity score matching, 14,220 patients remained in each cohort. Patients with CMD had a higher risk of TKA than controls at 12 months (HR 1.696, 95% CI 1.537-1.871), 24 months (HR 1.607, 95% CI 1.484-1.740), and 36 months (HR 1.598, 95% CI 1.485-1.720). Among individual cardiometabolic conditions, hypertension (HR 1.597, 95% CI 1.437-1.775) and hyperlipidemia (HR 1.373, 95% CI 1.184-1.594) were associated with increased TKA risk, whereas isolated T2DM was not significantly associated with TKA risk (HR 0.947, 95% CI 0.669-1.342). Kaplan-Meier analysis demonstrated lower TKA-free survival probabilities in the CMD group.</p><p><strong>Conclusion: </strong>CMD was associated with poorer clinical trajectories in patients with knee OA receiving intra-articular HA therapy. These findings suggest that metabolic health may be associated with treatment outcomes and may help identify patients at increased risk of progression to total knee arthroplasty.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261467265"},"PeriodicalIF":3.3,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13385613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148550448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of dry needling combined with exercise therapy versus exercise alone for pain and functional outcomes in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.","authors":"Muhammad Tayyab, Ameer Afzal Khan, Rahman Syed, Suleman Shah, Mohammed Al Meqbaali, Anfal Khan, Mohammed Al Sinani","doi":"10.1177/1759720X261463350","DOIUrl":"10.1177/1759720X261463350","url":null,"abstract":"<p><strong>Background: </strong>Knee osteoarthritis (KOA) is a leading cause of chronic pain and disability worldwide. Although exercise therapy is the recommended first-line treatment, many patients continue to experience pain and functional limitations. Dry needling (DN) has emerged as a potential adjunct therapy targeting myofascial and neuropathic pain mechanisms.</p><p><strong>Objectives: </strong>To evaluate the effectiveness of DN combined with exercise therapy compared with exercise therapy alone for pain reduction and functional improvement in patients with KOA.</p><p><strong>Design: </strong>Systematic review and meta-analysis of randomized controlled trials.</p><p><strong>Data sources and methods: </strong>A systematic search of PubMed, ClinicalTrials.gov, and the Cochrane Library was conducted from inception to October 23, 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Studies involving adults with KOA comparing DN plus exercise with exercise alone or sham DN plus exercise were included. The primary outcome was pain intensity (Visual Analog Scale/Numeric Pain Rating Scale), while secondary outcomes included WOMAC scores, neuropathic pain, functional performance, and psychosocial measures. Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was assessed with the <i>I</i> ² statistic, and risk of bias was evaluated using the Cochrane RoB-2 tool.</p><p><strong>Results: </strong>Six randomized controlled trials involving 453 participants were included. Compared with exercise alone, DN plus exercise significantly reduced pain at 3 months (MD -1.91; 95% CI -2.60 to -1.21; <i>I</i> ² = 66%). Significant improvements were also observed in WOMAC pain, stiffness, and physical function at short- and mid-term follow-up. Long-term outcomes (6-12 months) showed favorable trends, although CIs were wider.</p><p><strong>Conclusion: </strong>DN combined with exercise therapy may offer short- to mid-term improvements in pain and function in patients with KOA compared with exercise alone. However, the evidence is limited by a small number of studies, moderate certainty, and substantial heterogeneity, warranting cautious interpretation. The long-term benefits remain uncertain. <b><i>Trial registration</i>:</b> PROSPERO (Registration ID: (CRD420261285294)).</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261463350"},"PeriodicalIF":3.3,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13365652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Diagnosis and therapeutic management of psoriatic arthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA)\".","authors":"","doi":"10.1177/1759720X261468104","DOIUrl":"https://doi.org/10.1177/1759720X261468104","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/1759720X261436463.].</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261468104"},"PeriodicalIF":3.3,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13346741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148424336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restricted cubic spline analysis of treatment duration before tocilizumab withdrawal and relapse risk in rheumatoid arthritis.","authors":"Houhui Jiang, Yuxin Yan, Sheng Zhao, Rui Wu","doi":"10.1177/1759720X261464266","DOIUrl":"10.1177/1759720X261464266","url":null,"abstract":"<p><strong>Background: </strong>Tocilizumab (TCZ), an interleukin-6 receptor inhibitor, is effective for moderate to severe rheumatoid arthritis (RA). However, maintaining remission after TCZ withdrawal remains challenging, and the treatment duration required before discontinuation to minimize relapse risk is unclear.</p><p><strong>Objectives: </strong>To identify a TCZ treatment-duration threshold before withdrawal that is associated with a lower risk of relapse in patients with RA.</p><p><strong>Design: </strong>This was a retrospective study including 97 patients with RA who discontinued intravenous TCZ after stable disease control.</p><p><strong>Methods: </strong>We retrospectively analyzed 97 RA patients who achieved remission or low disease activity prior to TCZ withdrawal. The primary outcome was relapse within 12 months post-discontinuation. Cox proportional hazards regression identified independent predictors, while restricted cubic spline (RCS) modeling assessed non-linear associations between treatment duration and relapse risk. A simplified risk stratification tool was developed and internally validated using bootstrap resampling.</p><p><strong>Results: </strong>Among 97 patients with RA who discontinued TCZ after stable disease control, most were biologic-naïve (98.9%), the mean disease duration was 72.9 ± 52.7 months, and concomitant methotrexate and hydroxychloroquine were used in 73.2% and 47.4% of patients, respectively. During the 12-month follow-up, 54 patients (55.7%) relapsed. TCZ treatment duration was an independent protective factor (adjusted HR = 0.892 per month, <i>p</i> = 0.002), whereas anti-citrullinated protein antibody (ACPA) positivity was associated with increased relapse risk (adjusted HR = 2.122, <i>p</i> = 0.031). RCS analysis demonstrated an L-shaped non-linear relationship, identifying an empirically derived duration threshold at approximately 200 days associated with lower relapse risk. A simplified score assigning 1 point each for ACPA positivity and TCZ duration < 200 days stratified patients into low- (0 points), intermediate- (1 point), and high-risk (2 points) groups, with relapse rates of 27.3%, 53.8%, and 91.7%, respectively; the model showed acceptable discrimination (AUC = 0.76).</p><p><strong>Conclusion: </strong>Longer TCZ treatment duration and ACPA negativity were associated with a lower risk of relapse after TCZ withdrawal. An approximately 200-day treatment duration may serve as a clinically informative threshold for risk-stratified withdrawal decisions in routine practice, although disease control after withdrawal should be interpreted in the context of ongoing background therapy rather than confirmed drug-free remission.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261464266"},"PeriodicalIF":3.3,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13333046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping emotional function in fibromyalgia: integrating alexithymia, pain catastrophizing, and self-compassion.","authors":"Francesca Trunfio, Onorina Berardicurti, Rosa Bruni, Damiano Currado, Barbara Biticchi, Erika Corberi, Francesca Saracino, Lyubomyra Kun, Annalisa Marino, Ludovica Lamberti, Leonardo Frascà, Antonio Orlando, Andrea Pilato, Sebastiano Lorusso, Francesco Cimino, Alessandra Pia Crocitta, Dario Nejat, Lorenzo Fusco, Gianmarco Coluccia, Swathy Jayakrishnan, Irene Genovali, Marta Gatti, Marta Vomero, Vasiliki Liakouli, Roberto Giacomelli, Luca Navarini","doi":"10.1177/1759720X261421707","DOIUrl":"10.1177/1759720X261421707","url":null,"abstract":"<p><strong>Background: </strong>Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive dysfunction. Alexithymia-difficulty identifying and describing emotions-has been reported in up to 48% of FM patients and is associated with increased psychological distress and pain intensity, yet its specific contribution to FM remains unclear.</p><p><strong>Objectives: </strong>This study aimed to assess the interplay among alexithymia, self-compassion, pain catastrophizing, and hope to inform future integrated and emotion-focused treatment strategies for FM.</p><p><strong>Design: </strong>We conducted a cross-sectional investigation, consecutively recruiting 112 Caucasian women meeting the 2016 American College of Rheumatology criteria for FM between October 2023 and June 2024.</p><p><strong>Methods: </strong>Socio-demographic, clinical, and psychometric data were collected at baseline. Disease burden was evaluated using the Widespread Pain Index, Symptom Severity Scale (SSS), Polysymptomatic Distress Scale, modified Fibromyalgia Assessment Scale, and revised Fibromyalgia Impact Questionnaire (FIQ-R). Psychological constructs were assessed using the Toronto Alexithymia Scale (TAS-20), Adult Hope Scale, Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and Self-Compassion Scale (SCS). Participants were stratified into non-alexithymic, borderline, and alexithymic groups according to TAS-20 thresholds. Group differences were analyzed through χ² or Kruskal-Wallis tests, and associations were examined using univariable and multivariable linear regression models (α = 0.05).</p><p><strong>Results: </strong>Alexithymic traits were identified in 51.8% of patients. Individuals with alexithymia exhibited significantly higher anxiety, depression, and total HADS scores (all <i>p</i> < 0.01), greater pain catastrophizing (<i>p</i> = 0.003), and lower levels of hope (<i>p</i> < 0.05). Two self-compassion components, self-judgment and overidentification, were also significantly impaired (<i>p</i> = 0.012). Univariable analyses showed that alexithymia was positively associated with FM severity indices (SSS, FIQ-R) and psychological distress and negatively associated with hope and several self-compassion domains (all <i>p</i> < 0.001). In multivariable models, SSS (<i>p</i> < 0.001), PCS-Helplessness (<i>p</i> = 0.005), and SCS-Overidentification (<i>p</i> = 0.020) emerged as significant independent associated variables.</p><p><strong>Conclusion: </strong>Alexithymia represents a prominent marker of emotional vulnerability in FM, closely linked to symptom severity, maladaptive pain coping, and reduced hope and self-compassion. Integrating these constructs into FM assessment and management may support more comprehensive, emotion-focused therapeutic approaches.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261421707"},"PeriodicalIF":3.3,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends and future projections of hand osteoarthritis burden in China from 1990 to 2021.","authors":"Yijia Gao, Lei Chen, Siwei Yang, Fengyuan Yu, Baoxuan Lin, Botao Zhou, Yingjun Nie","doi":"10.1177/1759720X261460128","DOIUrl":"10.1177/1759720X261460128","url":null,"abstract":"<p><strong>Background: </strong>Hand osteoarthritis (HOA) is a prevalent degenerative joint disorder that causes pain, functional disability, and considerable socioeconomic burden. China's rapid population aging and widespread engagement in repetitive manual labor may have accelerated to the rise of HOA. However, long-term trends and future projections of its disease burden remain insufficiently characterized.</p><p><strong>Objective: </strong>To describe trends in HOA incidence, prevalence, and DALYs from 1990 to 2021, examine differences across age and sex, and project future disease burden.</p><p><strong>Design: </strong>A population-based descriptive study using GBD 2021 data to examine trends and project the burden of hand osteoarthritis in Chinese adults aged 30 years and older across national and subnational regions.</p><p><strong>Methods: </strong>Age-standardized incidence rate (ASIR), prevalence rate (ASPR), and disability-adjusted life year rate (ASDR) were analyzed by sex and age group. Temporal trends were quantified using Joinpoint regression to calculate annual and average annual percent changes (APC, AAPC), and future trends were projected to 2036 using an autoregressive integrated moving average (ARIMA) model.</p><p><strong>Results: </strong>Between 1990 and 2021, the burden of HOA increased substantially worldwide, with China showing a faster rise than the global average. In China, ASIR rose from 59.12 to 92.70 per 100,000, ASPR from 988.51 to 1603.85, and ASDR from 31.57 to 51.26, corresponding to AAPCs of 1.46%-1.58%. Females experienced consistently higher rates than males and faster growth. The disease burden rose sharply after age 50 and peaked between 65 and 79 years. Joinpoint analysis revealed multiple inflection points, with the steepest acceleration occurring from 2015 to 2019 (APC >5%). ARIMA projections indicate that male rates will plateau or slightly decline by 2035, whereas female rates will continue rising, potentially exceeding 150 per 100,000 for incidence and 3000 per 100,000 for prevalence.</p><p><strong>Conclusion: </strong>The burden of HOA in China is increasing rapidly and is likely associated with population aging, sex-specific biological vulnerability, and occupational exposure. Women and elderly adults are disproportionately affected, with widening sex and age disparities. Targeted interventions-including ergonomic protection, menopausal health management, and early rehabilitation-are essential to mitigate the projected rise in disease burden and to improve musculoskeletal health in an aging population.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261460128"},"PeriodicalIF":3.3,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision medicine in systemic sclerosis: back to the bedside.","authors":"Muriel Elhai","doi":"10.1177/1759720X261463363","DOIUrl":"10.1177/1759720X261463363","url":null,"abstract":"","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261463363"},"PeriodicalIF":3.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13309671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}